Recent Updates
Recently added Catalysts
MIRM Positive Sentiment

Resumen: Mirum Pharmaceuticals anuncia que se ha cumplido el criterio de valoración principal en el estudio de fase III AZURE-1 sobre brelovitug para tratar la hepatitis crónica por el virus delta

Tuesday, September 29, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Mirum Pharmaceuticals has announced the successful achievement of the primary endpoint in the Phase III AZURE-1 study. This study evaluates brelovitug, a fully human monoclonal antibody targeting the hepatitis B surface antigen, for treating chronic hepatitis delta virus infection. The results could pave the way for new treatment options in this area.

Market Sentiment Analysis

POSITIVE FACTORS

  • Mirum Pharmaceuticals met the primary endpoint in the Phase III AZURE-1 study.
  • Brelovitug shows promise as a treatment for chronic hepatitis delta virus.
  • The study's success may lead to new therapeutic options for patients.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~36 mo
Minimal dilution risk
Lead asset
Blinded CDCA
Phase 3 · CTX

Full Press Release Details

FOSTER CITY, California.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), una empresa líder en el ámbito de las enfermedades raras, ha anunciado hoy que se ha cumplido el criterio de valoración principal en la parte de fase III del estudio AZURE-1, que evalúa el brelovitug, un anticuerpo monoclonal totalmente humano en fase de investigación que se une al antígeno de superficie de la hepatitis B (HBsAg), para tratar la hepatitis crónica por el virus delta (HDV). El comunicado en el

Frequently Asked Questions

What is brelovitug?

Brelovitug is a fully human monoclonal antibody targeting the hepatitis B surface antigen.

What was the outcome of the AZURE-1 study?

The AZURE-1 study successfully met its primary endpoint for treating chronic hepatitis delta virus.

What disease does brelovitug aim to treat?

Brelovitug aims to treat chronic hepatitis delta virus infection.

Which company developed brelovitug?

Brelovitug was developed by Mirum Pharmaceuticals.

ShareAdd on Google
Tags: MIRM Mirum Pharmaceuticals brelovitug hepatitis delta AZURE-1 study Phase III
Last updated: Sep 29, 2026

Biotech snapshot

Cash runway
$561M liquidity · $15M/mo burn
~36 mo
Minimal dilution risk
Lead asset
Blinded CDCAPhase 3
CTX →